From Terminal to Chronic: 7-Year Follow-Up Data from the CROWN Study

The therapeutic landscape for oncogene-addicted non-small cell lung cancer (NSCLC) has shifted dramatically over the past decade. The introduction of first-generation tyrosine kinase inhibitors (TKIs) demonstrated that targeting driver oncogenes could substantially improve outcomes compared with cytotoxic chemotherapy. However, traditional standard-of-care front-line therapies have routinely been limited by two major clinical barriers: the eventual, inevitable emergence of on-target resistance mutations and the failure to provide durable, long-term protection against central nervous system (CNS) progression. For patients harboring rearrangements of the anaplastic lymphoma kinase ALK gene—representing approximately 4% of advanced NSCLC cases—the clinical objective has rapidly moved beyond achieving short-term tumor response toward maintaining deep, prolonged systemic and intracranial control.

ASCO Abstract Presentation

The newly released, long-term post hoc analysis from the global, randomized Phase 3 CROWN study presents an extraordinary milestone in thoracic oncology. With up to 7 years of follow-up data, this trial directly compares the third-generation macrocyclic ALK TKI lorlatinib with the first-generation standard, crizotinib, as first-line therapy for treatment-naïve advanced ALK-positive NSCLC. The long-term updates not only validate the sustained efficacy of lorlatinib but also establish a new landmark for progression-free survival (PFS) across all oncogene-driven solid tumors.

Why It Matters

Unprecedented Survival Curves and Disease Control

To contextualize why the 7-year update of the CROWN trial represents a paradigm shift, one must look closely at the survival kinetics. In the intention-to-treat population (n = 296), treatment-naïve patients were randomized 1:1 to receive either lorlatinib 100 mg once daily (n = 149) or crizotinib 250 mg twice daily (n = 147). At a median follow-up of 83.0 months for the lorlatinib cohort and 77.2 months for the crizotinib cohort, the hazard ratio (HR) for disease progression or death was an astounding (0.19, 95% CI, 0.13–0.26). Crucially, the median progression-free survival (mPFS) by investigator assessment was still not reached (NR) in the lorlatinib group (95% CI, 68.5–NR), compared to just 9.1 months (95% CI, 7.4–10.9) in the crizotinib cohort.

At the 7-year mark, the estimated proportion of patients alive and free from disease progression was 55% in the lorlatinib arm compared to a meager 3% in the crizotinib arm. This represents the longest PFS duration ever documented with single-agent molecularly targeted therapy in advanced NSCLC and across metastatic solid tumors globally.

A deeper analysis of the progression kinetics demonstrates an intriguing stabilization effect. Within the first 24 months of lorlatinib therapy, the probability of disease progression or death was approximately 30%. However, after surviving the first two years without a progression event, the hazard curve flattened dramatically. The estimated proportion of patients experiencing a PFS event during each subsequent yearly interval dropped and stabilized at a mere 3% per year over the next 5 years. Consequently, conditional PFS modeling demonstrated that patients who remained progression-free at 24 months had a 79% probability of maintaining that survival status without progression at year 7. This underscores the critical clinical principle of maximizing deep front-line response: suppressing the disease completely within the first 24 months yields a prolonged plateau where advanced NSCLC effectively mimics a well-managed chronic medical condition.

Furthermore, the data reveal that lorlatinib effectively stops the molecular clock of tumor evolution. Blood-based circulating tumor DNA (ctDNA) next-generation sequencing (NGS) analysis utilizing a 755-gene panel showed that no emerging new ALK resistance mutations were detected at the end of treatment in patients who eventually progressed on lorlatinib. Instead, resistance was driven primarily by complex bypass signaling pathways (e.g., alterations in RTK/RAS/MAPK signaling, tumor suppressor genes, DNA damage repair mechanisms, and gene amplifications MYC, MET, and NOTCH2 without any single dominant pathway emerging. By preventing the on-target kinase domain mutations that typically defeat first- and second-generation TKIs, lorlatinib imposes a profound barrier to tumor escape, explaining the sustained clinical durability observed over seven years.

Who It Affects

Broad-Spectrum Efficacy and Intracranial Protection

The clinical benefits of front-line lorlatinib are not restricted to an elite subpopulation; the benefit is consistently observed across all prespecified clinical subgroups. This includes Asian and non-Asian demographics, patients under or over 65 years of age, and, most importantly, patients stratified by central nervous system (CNS) metastatic status at baseline. Brain metastases are a historical hallmark of ALK-positive NSCLC, affecting up to 40% of patients at initial diagnosis and eventually developing in the vast majority of patients treated with older-generation TKIs due to poor blood-brain barrier penetration.

Patients with Baseline Brain Metastases

For patients who presented with measurable or nonmeasurable brain metastases at study entry, lorlatinib delivered a remarkable reduction in the risk of systemic or intracranial progression. The HR for disease progression or death in this high-risk subgroup was (0.08, 95% CI, 0.04–0.19). The median PFS for these patients on lorlatinib was an extraordinary 86.3 months (95% CI, 32.9–NR), contrasted against 6.0 months (95% CI, 3.7–7.6) for crizotinib. The 7-year PFS rate was 53% with lorlatinib, whereas every single patient in the crizotinib arm with baseline brain metastases had progressed or died within 24 months.

Patients Without Baseline Brain Metastases

For patients entering the trial without baseline CNS disease, lorlatinib acted as an unmatched prophylactic shield. The HR for systemic progression or death was (0.23, 95% CI, 0.16–0.34), with a median PFS that remains unreached and a 7-year PFS rate of 56% (vs. 4% for crizotinib). At 7 years, the probability of successfully preventing the development of new brain metastases was 96% with lorlatinib, compared to only 22% with crizotinib.

Across the entire intention-to-treat population, the median intracranial TTP was not reached with lorlatinib versus 16.4 months with crizotinib (HR = 0.06; 95% CI, 0.03–0.12). Astoundingly, no new intracranial progression events occurred after the first 30 months of therapy in the lorlatinib group. The intracranial survival curve becomes a perfectly flat line at 92% from month 30 out to month 96.

This “flat line” effect represents a unique clinical phenomenon. Emerging translational data suggest that lorlatinib’s multi-targeted profile—specifically its concurrent inhibition of wild-type Tropomyosin Receptor Kinase B (TrkB)—may actively restrict early brain metastatic seeding and microenvironmental colonization. This neuro-protective mechanism, which is completely missing in drugs lacking anti-TRK activity, reinforces lorlatinib as an essential front-line intervention for any patient where long-term CNS protection is a primary objective.

What Changes

Clinical Practice and Toxicity Management

The unprecedented survival data dictate a definitive change in clinical practice: lorlatinib must be prioritized as the preferred, standard-of-care first-line choice over older second-generation options like alectinib, brigatinib, or ensartinib. While historical cross-trial comparisons must be interpreted with caution, the long-term data for second-generation TKIs demonstrate median PFS values ranging between 26 and 35 months, with 4-year PFS rates of 36% to 44%. Lorlatinib’s 7-year PFS rate of 55% and unreached median PFS completely redefine what healthcare providers can promise their patients at diagnosis.

However, adopting lorlatinib in the first-line setting requires a fundamental shift in how clinicians manage treatment-related toxicities. Because patients will remain on this single-agent macrocyclic TKI for many years, proactive, long-term monitoring is paramount. The 7-year analysis confirmed that lorlatinib does not exhibit cumulative toxicity; the safety profile remained entirely consistent with the 5-year interim results, and treatment-related adverse events (AEs) did not lead to a single treatment discontinuation after the first 26 months.

Adverse Event Profile Summary (CROWN 7-Year Update)

While the Grade 3 or 4 all-causality AE rate appears high at 77%, the data reveal that this was predominantly driven by asymptomatic, easily managed lipid alterations: specifically, Grade 3/4 hypertriglyceridemia (26%) and hypercholesterolemia (22%). Clinicians must recognize that these metabolic shifts are on-target effects of lorlatinib’s structure and are highly responsive to standard lipid-lowering therapies (e.g., statins and fibrates). Strikingly, despite the high incidence of hyperlipidemia, the overall incidence of cardiovascular AEs remained extremely low and was actually lower in the lorlatinib arm than in the crizotinib arm among patients who had or developed hyperlipidemia (14% vs. 28% for treatment-related cardiovascular events).

Central nervous system AEs (including cognitive changes, mood alterations, and speech effects) occurred in 43% of patients, but 86% of these events were mild (Grade 1 or 2). Clinicians can confidently manage these symptoms using temporary dose interruptions or structural dose reductions. Over the 7-year follow-up, 34% of patients required an investigator-recommended dose reduction (17% to a single reduced dose, 17% to two reduced doses), with a median time to first reduction of 25 weeks.

A rigorous, post hoc landmark analysis at 7 years evaluated patients who underwent dose reductions within the first 26 weeks of treatment. The analysis conclusively showed that early dose reductions did not compromise either systemic or intracranial efficacy. Multivariable Cox proportional hazards modeling, treating dose as a time-varying covariate (100 mg vs. 75 mg vs. 50 mg), confirmed no statistically significant difference in PFS or intracranial TTP across the three dose levels.

This is a vital takeaway for the clinical team: providers should not hesitate to reduce the dose of lorlatinib to preserve a patient’s quality of life. Modifying the dose to 75 mg or 50 mg daily resolves or mitigates peripheral neuropathy, cognitive shifts, and weight gain without sacrificing the deep, long-term oncological control that the drug provides.

Conclusions for Practice

The 7-year update of the Phase 3 CROWN study establishes front-line lorlatinib as an unparalleled therapeutic standard for advanced ALK-positive NSCLC. By achieving a 7-year PFS rate of 55%, a 96% brain metastasis prevention rate, and a complete cessation of new intracranial progression events after 30 months, lorlatinib provides the clinical tools required to transform an advanced, historically aggressive malignancy into a highly manageable, long-term chronic condition. Through proactive management of metabolic and cognitive changes and the strategic utilization of dose reductions without loss of efficacy, healthcare providers can offer patients an enduring period of disease control that completely redefines the boundaries of modern targeted oncology.

Reference

1. Shaw AT, Solomon BJ, Felip E, et al. Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small cell lung cancer: 7-year update from the phase 3 CROWN study. Ann Oncol. Published online May 29, 2026. doi:10.1016/j.annonc.2026.05.692